NCT00158808已完成2 期
Assess the Immunogenicity &d Reactogenicity of a Booster Dose of a Formulation of GSK Biologicals' DTPw-HBV/Hib Vaccine at 15-18 Mths of Age in Infants Previously Primed With the Same Vaccine
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 1
- 主要终点
- Anti-PRP antibody concentration one month after the booster dose (in groups boosted with the DTPw-HBV/Hib vaccine).
研究概览
简要总结
To assess the anti-PRP antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of DTPw-HBV/Hib vaccine
详细描述
All subjects were previously primed with one of the two formulations of the combined DTPw-HBV/Hib vaccine. At the age of 10 months, 50% of each group received a plain PRP challenge to assess the immune memory to PRP. In this booster study in the second year of life, all subjects who received DTPw-HBV/Hib and plain PRP will receive DTPw-HBV as a booster vaccination. All other subjects will receive as booster the same vaccine they received in the primary vaccination study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 15 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
- •A male or female of at least 15 months of age at the time of the booster vaccination, who had previously received 3-dose primary vaccination and, if applicable, plain-PRP vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering the study.
排除标准
- •for enrolment
- •Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before and ending 30 days after administration of study vaccines with the exception of oral polio vaccine (OPV).
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
- •Previous booster vaccination against diphtheria, tetanus, pertussis, hepatitis B or Hib with the exception of plain PRP challenge.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
结局指标
主要结局
Anti-PRP antibody concentration one month after the booster dose (in groups boosted with the DTPw-HBV/Hib vaccine).
次要结局
- Immunology
- At the time of the booster dose: concentrations of antibodies against all vaccine antigens (diphtheria, tetanus, pertussis, hepatitis B and Hib antigens)
- Reactogenicity and Safety
- Occurrence of solicited symptoms during the specific follow-up period after the booster dose.
- Occurrence of serious adverse events (SAEs) during the entire study period."
- One month after the booster dose: concentrations of antibodies against all vaccine antigens (diphtheria, tetanus, pertussis, hepatitis B and Hib antigens)
- Occurrence of unsolicited symptoms during the specific follow-up period after the booster dose .
研究者
研究点 (1)
Loading locations...
相似试验
未知
Unknown
Clinical studies on PRP antibody titer after administration with Haemophilus influenzae type b conjudate vaccine.ot applicableJPRN-jRCT1080223268The Chemo-Sero-Therapeutic Research Institute
已完成
4 期
Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in MaliDiarrhea RotavirusNCT02286895PATH600
已完成
3 期
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationInfections, MeningococcalNCT01777308GlaxoSmithKline156
已完成
3 期
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate VaccineInfections, StreptococcalNCT00370227GlaxoSmithKline390
已完成
3 期
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsDiphtheriaTetanusPertussisPoliomyelitisHepatitis BNCT00303316Sanofi458